ITGAM and neoplasm: Q702 treatment for 5 days reduced the percentage of tumor-infiltrating CD11b+Ly6G−Ly6C+ monocytes (monocytic MDSCs, M-MDSCs) by 2.3-fold from 12% to 5.3%.